Search
Cupric Chloride
go.drugbank.com/drugs/DB09131ApprovedCupric chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).
Mixtures: Tracel Injektionslösung in einer Fertigspritze, Trace Elements Solution InjSynonyms: copper(II) chlorideColestipol
go.drugbank.com/drugs/DB00375Approved[FDA Label, F4555, F4567, L6262] In particular, as colestipol's general mechanism of action ultimately results in the decreased absorption and enhanced secretion of bile acids and lipids in the feces … Bile acid sequestrants like colestipol have been in use since the 1970s.
Categories: Compounds used in a research, industrial, or household settingCoagulation factor X human
go.drugbank.com/drugs/DB13148ApprovedInvestigationalInherited factor X deficiency is a rare autosomal recessive bleeding disorder that is estimated to occur in 1:1 000 000 individuals up to 1:500 carriers [A31471]. … Coagulation Factor X is a vitamin K-dependent, liver-produced serine protease that serves as the first enzyme in the coagulation cascade to form fibrin.
Mixtures: COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET, COFACT 500 IU/20 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADETDegarelix
go.drugbank.com/drugs/DB06699ApprovedInvestigationalChemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008. … Reduction in testosterone is important in treating men with advanced prostate cancer.
Ethinylestradiol
go.drugbank.com/drugs/DB00977ApprovedInvestigationalEthinylestradiol was first synthesized in 1938 by Hans Herloff Inhoffen and Walter Hohlweg at Schering.[A191107] It was developed in an effort to create an estrogen with greater oral bioavailability. … [A191107] These properties were achieved by the substitution of an ethinyl group at carbon 17 of [estradiol].[A191107] Ethinylestradiol soon replaced [mestranol] in contraceptive pills.
Mixtures: Lenea 20 µg/75 µg überzogene Tabletten, PIL KB I KOMBINASICapsaicin
go.drugbank.com/drugs/DB06774ApprovedInvestigationalCapsaicin is most often used as a topical analgesic and exists in many formulations of cream, liquid, and patch preparations of various strengths; however, it may also be found in some dietary supplements … Capsaicin is a naturally-occurring botanical irritant in chili peppers, synthetically derived for pharmaceutical formulations.
Mixtures: Tianhe Gutong Tiegao (in Polyisobutylene Carrier), Medi-derm / L With LidocaineCategories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesZolbetuximab
go.drugbank.com/drugs/DB15118ApprovedInvestigational[L51923] It is specifically targeted against CLDN18.2, a membrane protein normally found in gastric mucosal cells which is overexpressed in 30-50% of gastric and gastroesophageal junction (GEJ) adenocarcinomas … [A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923]
Pectin
go.drugbank.com/drugs/DB11158ApprovedInvestigationalVet approvedPectin is a heteropolysaccharide commercially derived from the cell wall of higher plants.[A32327] It is composed of partially methylated polygalacturonic acid units linked in the positions 1-4. … [L1961] The carboxylic group of the constituents of pectin can exist in the form of esters, free acids, ammonium, potassium or sodium salts or as acid amides.
Mixtures: NEOKAP-LF, NEOKAP-LFCategories: Compounds used in a research, industrial, or household settingClofarabine
go.drugbank.com/drugs/DB00631ApprovedInvestigationalClofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. … Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed.
Categories: OCT2 Substrates with a Narrow Therapeutic Index, OAT3/SLC22A8 Substrates with a Narrow Therapeutic IndexSynonyms: Cl-F-Ara-ALorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalinclude lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. … Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018